An update to our reporting on recently-approved Alzheimer’s drugs. You may recall FDA advisers and many independent watchdogs said there’s no good evidence the hugely expensive shots make a meaningful difference, and they could cause serious side effects. But the […]
The following is an excerpt from Science. Cassava Sciences, a biotech company whose work on the experimental Alzheimer’s drug simufilam has been heavily criticized and is the subject of ongoing federal probes, has suffered another blow. A much-anticipated investigation by
Alzheimer’s drug developer cited for ‘egregious misconduct’ Read More »
Now an important update to our coverage of a new Alzheimer’s drug that drew so much controversy. Aducanumab was approved without one yes vote from the FDA advisory committee. In fact, several members quit over it. And critics say it
The following is an excerpt from MedPage Today. A doctor and a drug rep from Ohio pleaded guilty on Monday to their roles in a kickback scheme that pushed prescriptions for dextromethorphan/quinidine (Nuedexta) onto patients who didn’t need it, according to the
Doctor, drug rep plead guilty in Nuedexta drama Read More »
An update on our coverage of the Alzheimer’s drug Aduhelm. And a resident of San Francisco’s drug-riddled Tenderloin District talks about the nightmarish turn she says the neighborhood has taken with the City’s permission.
After Hours: Alzheimer’s Drug Update & San Francisco’s Open-Air Drug Market (Podcast) Read More »
The following is an excerpt from Medpage Today. A man treated with the recently approved Alzheimer’s drug aducanumab (Aduhelm) had six amyloid-related imaging abnormality (ARIA) episodes, researchers reported. Over 44 months in a long-term extension study, the Alzheimer’s disease patient
Click here to watch the investigation on Alzheimer’s drug that aired prior to its approval The FDA has just approved a new treatment for early Alzheimer’s that’s being billed as the first potential “cure” that addresses the root cause rather
Alzheimer’s drug approved despite not one FDA adviser recommending it Read More »
